• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Procaps Group S.A.

    5/1/24 4:10:31 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PROC alert in real time by email
    NT 20-F 1 ea0205111-nt20f_procaps.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

       

    SEC FILE NUMBER

    001-40851

       

    CUSIP NUMBER

    L7756P 102

     

    (Check one):   ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D
        ☐ Form N-CEN ☐ Form N-CSR      
                 
        For Period Ended:   December 31, 2023    
        ☐ Transition Report on Form 10-K    
        ☐ Transition Report on Form 20-F    
        ☐ Transition Report on Form 11-K    
        ☐ Transition Report on Form 10-Q    

    For the Transition Period Ended:  

     

    Read Instructions (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

     

    PART I — REGISTRANT INFORMATION

     

    Procaps Group, S.A.
    Full Name of Registrant
     
     
    Former Name if Applicable
     
    9 rue de Bitbourg, L-1273
    Address of Principal Executive Office (Street and Number)
     
    Luxembourg, Grand Duchy of Luxembourg, R.C.S. Luxembourg: B253360
    City, State and Zip Code

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Procaps Group, S.A. (the “Company”) has determined that it is unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the “Form 20-F”) within the prescribed time period without unreasonable effort and expense because additional time is necessary to prepare and complete the Company’s review of its financial statements for the year ended December 31, 2023, in order for the Company to file its annual report on Form 20-F, including with respect to an ongoing internal investigation initiated by the Company’s Audit Committee with the assistance of external advisors into matters involving the Company’s historical accounting treatment and associated financial statement disclosure related to a 2012 loan in the amount of $2.5 million that involved related parties. The Company is working diligently to complete the review of its financial statements and the aforementioned internal investigation in order to file its Form 20-F as soon as practicable within the fifteen-day grace period provided by Rule 12b-25 under the Securities Exchange Act of 1934.

     

    2

     

     

    PART IV — OTHER INFORMATION

     

    Name and telephone number of person to contact in regard to this notification
     
    Melissa Angelini   305   308-8434
    (Name)   (Area Code)   (Telephone Number)
     
    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
     
            ☒ Yes ☐ No
             
    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
     
            ☒ Yes ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Company has made preliminary determinations of certain results of operations. Revenue for the year ended December 31, 2023, is currently expected to be between approximately $425 and $433 million, compared to $409.9 million for the year ended December 31, 2022, with the difference primarily due to an increase in sales. Income for the year ended December 31, 2023, is currently expected to be between approximately $50 and $55 million, compared to income of $42.5 million for the year ended December 31, 2022, with the difference primarily due to the accounting treatment for non-cash shares and warrants held in escrow and an increase in non-recurring income.

     

    Because the Company has not yet completed the preparation and review of its financial statements and because of the forward-looking nature of the estimated Adjusted EBITDA presented below, the Company does not have specific quantifications of the amounts that would be required to provide a reconciliation of income, the most directly comparable financial measure calculated and presented in accordance with IFRS to Adjusted EBITDA for the year ended December 31, 2023. The Company believes there is a degree of variability with respect to certain of the IFRS measures and certain adjustments made to arrive at the relevant non-IFRS measure that precludes the Company from providing an accurate preliminary estimate of an IFRS to non-IFRS reconciliation without unreasonable effort or expense. With reference to the foregoing and the below disclosures regarding the use of non-IFRS measures, the Company currently expects Adjusted EBITDA for the year ended December 31, 2023 to present single-digit growth in comparison with Adjusted EBITDA for the year ended December 31, 2022.

     

    The unaudited financial information set out above is preliminary and subject to potential adjustments, which could result in significant differences from this preliminary unaudited financial information.

     

    Use of Non-IFRS Financial Measures

     

    The Company’s management uses and discloses Adjusted EBITDA and other measures which represent “non-IFRS” financial information to assess its operating performance across periods and for business planning purposes. The Company’s management believes the presentation of these non-IFRS financial measures is useful to investors as it provides additional information to facilitate comparisons of historical operating results, identify trends in our underlying operating results and provide additional insight and transparency on how we evaluate our business. These non-IFRS measures are not meant to be considered in isolation or as a substitute for financial information presented in accordance with International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board and should be viewed as supplemental and in addition to our financial information presented in accordance with IFRS.

     

    The Company’s management defines EBITDA as profit (loss) for the period before interest expense, net, income tax expense and depreciation and amortization. The Company’s management defines Adjusted EBITDA as EBITDA further adjusted to exclude certain isolated costs incurred as a result of the COVID-19 pandemic, certain transaction costs incurred in connection with the business combination (“Business Combination”) with Union Acquisition Corp. II, certain listing expenses incurred in connection with the Business Combination, certain costs related to business transformation initiatives, certain foreign currency translation adjustments and certain other finance costs, and other nonrecurring nonoperational or unordinary items as the Company may deem appropriate from time to time. We also report Adjusted EBITDA as a percentage of net revenue as an additional measure so investors may evaluate our Adjusted EBITDA margins. Neither EBITDA or Adjusted EBITDA are presented in accordance with generally accepted accounting principles or IFRS and are non-IFRS financial measures.

     

    3

     

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, the Company’s expectations as to the outcome of its preparation and review of its financial statements and preliminary determinations of certain financial results.

     

    These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Factors that may cause future results to differ materially from management’s current expectations include, among other things, the discovery of additional information relevant to the review of the Company’s financial statements; the conclusions of management (and the timing of the conclusions) concerning matters relating to the Company’s financial statements; the timing of the review by, and the conclusions of, the Company’s independent registered public accounting firm regarding the Company’s financial statements; the possibility that errors may be identified; and the risk that the completion and filing of the Form 20-F will take longer than expected. The Company disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

     

    Procaps Group, S.A.

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date May 1, 2024 By /s/ José Antonio Toledo Vieira
        Name:  José Antonio Toledo Vieira
        Title: Chief Executive Officer

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

    4

     

     

    Get the next $PROC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PROC
    SEC Filings

    View All

    SEC Form 6-K filed by Procaps Group S.A.

    6-K - Procaps Group, S.A. (0001863362) (Filer)

    2/19/25 8:56:19 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Procaps Group S.A.

    6-K - Procaps Group, S.A. (0001863362) (Filer)

    2/3/25 9:00:03 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Procaps Group S.A.

    6-K - Procaps Group, S.A. (0001863362) (Filer)

    1/16/25 8:30:04 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Procaps Group Receives Delisting Notice From Nasdaq

    MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

    2/3/25 8:50:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Receives Additional Delinquency Letter

    MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

    1/3/25 4:15:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

    MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

    12/20/24 4:53:03 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Manieu Alexandre Weinstein claimed ownership of 15,877,516 units of Ordinary Shares

    3 - Procaps Group, S.A. (0001863362) (Issuer)

    10/12/21 9:32:55 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3: New insider Minski Ruben claimed ownership of 31,338,454 units of Ordinary Shares

    3 - Procaps Group, S.A. (0001863362) (Issuer)

    10/8/21 5:22:21 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3: New insider Minski Jose claimed ownership of 17,960,146 units of Ordinary Shares

    3 - Procaps Group, S.A. (0001863362) (Issuer)

    10/8/21 5:20:55 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Leadership Updates

    Live Leadership Updates

    View All

    Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

    MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

    12/20/24 4:53:03 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Statement from the Board of Directors of Procaps Group

    Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

    12/21/23 6:45:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

    Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

    11/22/23 8:30:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    10/29/24 9:46:26 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    10/28/24 8:42:14 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Financials

    Live finance-specific insights

    View All

    Procaps Group Reports Third Quarter 2023 Results

    Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

    12/26/23 5:40:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Update on Third Quarter Results

    Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

    11/14/23 5:25:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

    Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

    11/10/23 11:37:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care